2012
Genome‐wide association study of N370S homozygous Gaucher disease reveals the candidacy of CLN8 gene as a genetic modifier contributing to extreme phenotypic variation
Zhang CK, Stein PB, Liu J, Wang Z, Yang R, Cho JH, Gregersen PK, Aerts JM, Zhao H, Pastores GM, Mistry PK. Genome‐wide association study of N370S homozygous Gaucher disease reveals the candidacy of CLN8 gene as a genetic modifier contributing to extreme phenotypic variation. American Journal Of Hematology 2012, 87: 377-383. PMID: 22388998, PMCID: PMC3684025, DOI: 10.1002/ajh.23118.Peer-Reviewed Original ResearchMeSH KeywordsAllelesCells, CulturedEpistasis, GeneticFemaleFibroblastsGaucher DiseaseGenome-Wide Association StudyGenotypeGermanyGlucosylceramidaseHomozygoteHumansJewsMacrophagesMaleMembrane ProteinsMiddle AgedMutation, MissensePhenotypePolymorphism, Single NucleotidePsychosineSeverity of Illness IndexConceptsGaucher diseaseType 1 Gaucher's diseaseMild Gaucher diseaseSevere disease categoryCandidate modifier genesGlucosylceramide-laden macrophagesAshkenazi Jewish patientsRisk allele ACultured skin fibroblastsEligible patientsMild diseaseOdds ratioSevere diseaseGBA1 mutationsPatientsJewish patientsDisease severityDisease categoriesCLN8 geneRisk allelesDiseaseN370S mutationSeveritySkin fibroblastsGenetic modifiers
2011
Recombinant macrophage targeted enzyme replacement therapy for Gaucher disease in India
Nagral A, Mewawalla P, Jagadeesh S, Kabra M, Phadke SR, Verma IC, Puri RD, Gupta N, Kishnani PS, Mistry PK. Recombinant macrophage targeted enzyme replacement therapy for Gaucher disease in India. Indian Pediatrics 2011, 48: 779. PMID: 22080680, DOI: 10.1007/s13312-011-0128-4.Peer-Reviewed Original ResearchConceptsEnzyme replacement therapyReplacement therapyGaucher diseaseNeurological symptomsPlatelet countMean increaseImiglucerase enzyme replacement therapyBone marrow examinationCohort of patientsMonths of treatmentMild neurological symptomsImpairment of qualitySignificant neurological involvementBone painDesignRetrospective analysisLysosomal storage disorderMarrow examinationSymptomatic anemiaNeurological involvementIndian patientsSpleen volumeSpleen sizeGlucocerebrosidase levelsDrug infusionBone diseaseElevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response
Dekker N, van Dussen L, Hollak CE, Overkleeft H, Scheij S, Ghauharali K, van Breemen MJ, Ferraz MJ, Groener JE, Maas M, Wijburg FA, Speijer D, Tylki-Szymanska A, Mistry PK, Boot RG, Aerts JM. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood 2011, 118: e118-e127. PMID: 21868580, PMCID: PMC3685900, DOI: 10.1182/blood-2011-05-352971.Peer-Reviewed Original Research
2010
Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage
Mistry PK, Liu J, Yang M, Nottoli T, McGrath J, Jain D, Zhang K, Keutzer J, Chuang WL, Mehal WZ, Zhao H, Lin A, Mane S, Liu X, Peng YZ, Li JH, Agrawal M, Zhu LL, Blair HC, Robinson LJ, Iqbal J, Sun L, Zaidi M. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proceedings Of The National Academy Of Sciences Of The United States Of America 2010, 107: 19473-19478. PMID: 20962279, PMCID: PMC2984187, DOI: 10.1073/pnas.1003308107.Peer-Reviewed Original ResearchConceptsType 1 Gaucher diseaseThymic T cellsGene-deficient miceOsteoblastic bone formationWorthwhile therapeutic targetDendritic cellsSevere osteoporosisAutoimmune diseasesWidespread dysfunctionCytokine measurementsT cellsCell lineagesParkinson's diseaseTherapeutic targetGBA1 geneMononuclear phagocytesGaucher diseaseGlucocerebrosidase deficiencyMolecular dysregulationDiseaseInhibitory effectBone formationMultiple cell lineagesMesenchymal cell lineagesMacrophagesFocal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage‐targeted enzyme replacement therapy
Stein P, Malhotra A, Haims A, Pastores GM, Mistry PK. Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage‐targeted enzyme replacement therapy. Journal Of Inherited Metabolic Disease 2010, 33: 769-774. PMID: 20683668, PMCID: PMC3008694, DOI: 10.1007/s10545-010-9175-6.Peer-Reviewed Original ResearchConceptsFocal splenic lesionsEnzyme replacement therapyGD1 patientsReplacement therapySplenic lesionsMacrophage-targeted enzyme replacement therapyPlatelet responseYears of ERTPrevalence of osteonecrosisGaucher disease type IDeterminants of responseType IPoor plateletsAvascular osteonecrosisSuboptimal responseSevere manifestationsSplenic responseIntact spleenClinical significanceSplenic parenchymaPatientsWorse thrombocytopeniaRoutine evaluationSplenomegalyTherapyHigh incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease
Taddei TH, Dziura J, Chen S, Yang R, Hyogo H, Sullards C, Cohen DE, Pastores G, Mistry PK. High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease. Journal Of Inherited Metabolic Disease 2010, 33: 291-300. PMID: 20354791, PMCID: PMC3008397, DOI: 10.1007/s10545-010-9070-1.Peer-Reviewed Original ResearchConceptsPrevalence of gallstonesType 1 Gaucher diseaseBody mass indexBile lipid analysisGaucher diseaseLipoprotein cholesterolHigh low-density lipoprotein cholesterolLow high-density lipoprotein cholesterolHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolMultiple logistic regression analysisType 1 Gaucher's diseaseBile lipid compositionBiliary lipid secretionCholesterol gallstone diseaseLogistic regression analysisMetabolic syndromeGallstone diseaseLDL cholesterolStudy cohortLipoprotein profileMass indexFemale sexBile compositionBiliary lipids
1996
Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease
Mistry P, Wraight E, Cox T. Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease. The Lancet 1996, 348: 1555-1559. PMID: 8950883, DOI: 10.1016/s0140-6736(96)04451-0.Peer-Reviewed Original ResearchConceptsGaucher diseaseBone marrowType 1 Gaucher's diseaseActivity of glucocerebrosidaseReceptor-mediated uptakeAcid beta-glucosidase activityAnalysis of bloodAvid uptakeBolus injectionHigh doseGaucher cellsHealthy individualsTracer enzymeGamma scintigraphyReceptor activityMacrophage systemDiseaseLysosomal disordersPlacental enzymeTissue distributionHigh-affinity targetingSaturable uptakePrimary defectScintigraphyVivo
1995
Osteopontin Is Not a Marker for Proliferating Human Vascular Smooth Muscle Cells
Newman C, Bruun B, Porter K, Mistry P, Shanahan C, Weissberg P. Osteopontin Is Not a Marker for Proliferating Human Vascular Smooth Muscle Cells. Arteriosclerosis Thrombosis And Vascular Biology 1995, 15: 2010-2018. PMID: 7583583, DOI: 10.1161/01.atv.15.11.2010.Peer-Reviewed Original ResearchConceptsHuman vascular smooth muscle cellsOP gene expressionVascular smooth muscle cellsRat vascular smooth muscle cellsGene expressionRodent vascular smooth muscle cellsAsp cell-binding sequenceSmooth muscle cellsCell-binding sequenceOP mRNAMuscle cellsNorthern blot analysisCultured human vascular smooth muscle cellsNormal growth mediumMRNA expressionFibroblast growth factorBasic fibroblast growth factorBalloon carotid injuryCultured rat vascular smooth muscle cellsCultured human macrophagesLipid loadingGrowth mediumTGF beta 1Situ hybridization studiesSaphenous veinHigh Expression of Osteopontin mRNA in Human Macrophages but Not Human Vascular Smooth Muscle Cells in Culture
NEWMAN CM, BRUUN BC, MISTRY PK, WEISSBERG PL, SHANAHAN CM. High Expression of Osteopontin mRNA in Human Macrophages but Not Human Vascular Smooth Muscle Cells in Culture. Annals Of The New York Academy Of Sciences 1995, 760: 381-382. PMID: 7785923, DOI: 10.1111/j.1749-6632.1995.tb44663.x.Peer-Reviewed Original Research